Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

(GILT, IP, ODP, PROT.OB, NLY) Stock Report from




Gilat Satellite Networks Ltd. (Nasdaq:GILT), a worldwide leader in satellite networking technology, solutions and services, reported that it has entered into a definitive agreement to acquire all of the outstanding stock of Wavestream Corporation.

Wavestream is a leading provider of high power solid state amplifiers. Wavestream's family of Ka, Ku, X and C-band Solid State Power Amplifiers (SSPA) and Block Upconverters (BUC) provide systems integrators with field-proven, high performance solutions designed for mobile and fixed satellite communication (SATCOM) systems worldwide.

GILT expects to leverage Wavestream's technology and sales reach to further enhance Spacenet Integrated Government Solutions' (SIGS) market position in the government sector.


Global paper and packaging company International Paper Co. (NYSE: IP) declared common and preferred stock dividends for the October-December quarter. The common stock dividend amounts to 12.5 cents per share. IP also declared a quarterly dividend of $1 per share on its cumulative $4 preferred stock. Both dividends will be paid on Dec. 15 to shareholders of record on Nov. 16.


Office Depot, Inc. (NYSE: ODP) is in negotiations to sell its 46 stores in Israel to department store operator New Hamashbir Lazarchan Ltd. for $47 million. The amount is minus the outstanding debt at time of closing, and the subsequent licensing of trade names and intellectual property rights, said Boca Raton-based Office Depot (NYSE: ODP). New Hamashbir Lazarchan trades on the stock exchange in Tel Aviv under the symbol MSBZ.



Proteonomix, Inc.,  (OTCBB: PROT) is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives.

** PROT has filed a utility patent application for the Preparation and Use of Stromal Cells for Treatment of Cardiac Diseases.

This is another step in the development of PROT’s intellectual property and getting StromaCel into the commercial market.

The technology covered by the patent application will reduce the cost to the patient of this type of treatment and when trials are completed and regulatory approvals are obtained PROT believes that the stromal cell technology will have major importance in the treatment of cardiac damage caused by heart attacks.

PROT’s Chairman and CEO, Mr. Michael Cohen, is scheduling a multi-city European road trip to create additional awareness of PROT investment opportunity to institutional investors.

Without going into proprietary details, Mr. Cohen noted that the application relates to cell line expansion that he believes represents a fundamental improvement in the efficiency of producing stem cells which should have applications far beyond the cardiac therapy to which the present application relates.

More about PROT at


Annaly Capital Management, Inc. (NYSE: NLY) reported an adjustment to the conversion rate for 4.00% Convertible Senior Notes Due 2015 (the "Notes"). The adjustment to the conversion rate for the Notes is being made pursuant to the governing indenture for the Notes in light of the Company's previously announced third quarter 2010 common stock cash dividend of $0.68 per common share. The new conversion price for the Notes is $19.1556 per common share, effective September 30, 2010.

The conversion price for the Notes was previously $19.8915 per common share. The new conversion rate for each $1,000 principal amount of Notes is 52.2040 of the Company’s common shares. The conversion rate for each $1,000 principal amount of Notes was previously 50.2726 of the Company’s common shares. Notice of the conversion rate adjustment was delivered to security holders and Wells Fargo Bank, National Association, the trustee, in accordance with the terms of the governing indenture for the Notes.


Signup for FREE Daily Stock Alerts From


Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (OTCPK:PROT).